These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 6606676)
1. Anti-T cell monoclonal antibodies conjugated to ricin as potential reagents for human GVHD prophylaxis: effect on the generation of cytotoxic T cells in both peripheral blood and bone marrow. Quinones RR; Youle RJ; Kersey JH; Zanjani ED; Azemove SM; Soderling CC; Lebien TW; Beverley PC; Neville DM; Vallera DA J Immunol; 1984 Feb; 132(2):678-83. PubMed ID: 6606676 [TBL] [Abstract][Full Text] [Related]
2. Immunotoxins show rapid entry of diphtheria toxin but not ricin via the T3 antigen. Youle RJ; Uckun FM; Vallera DA; Colombatti M J Immunol; 1986 Jan; 136(1):93-8. PubMed ID: 3079613 [TBL] [Abstract][Full Text] [Related]
3. Elimination of clonogenic T-leukemic cells from human bone marrow using anti-Mr 65,000 protein immunotoxins. Stong RC; Youle RJ; Vallera DA Cancer Res; 1984 Jul; 44(7):3000-6. PubMed ID: 6372999 [TBL] [Abstract][Full Text] [Related]
4. Specific inhibition of in vitro lymphocyte transformation by an anti-pan T cell (gp67) ricin A chain immunotoxin. Kernan NA; Knowles RW; Burns MJ; Broxmeyer HE; Lu L; Lee HM; Kawahata RT; Scannon PJ; Dupont B J Immunol; 1984 Jul; 133(1):137-46. PubMed ID: 6609971 [TBL] [Abstract][Full Text] [Related]
5. Specific ex-vivo depletion of human bone marrow T lymphocytes by an anti-pan-T cell (CD5) ricin A-chain immunotoxin. Siena S; Villa S; Bonadonna G; Bregni M; Gianni AM Transplantation; 1987 Mar; 43(3):421-6. PubMed ID: 3103275 [TBL] [Abstract][Full Text] [Related]
6. T-cell depletion with ricin A-chain T101 in allogeneic bone marrow transplantation to prevent severe graft-versus-host disease. Fauser AA; Shustik C; Langleben A; Laurent G; Kanz L; Spurll GM; Price G; Ahlgren PD; Cooper BA Clin Invest Med; 1988 Feb; 11(1):40-6. PubMed ID: 3284672 [TBL] [Abstract][Full Text] [Related]
8. Specific killing of human T-leukemia cells by immunotoxins prepared with ricin A chain and monoclonal anti-human T-cell leukemia antibodies. Seon BK Cancer Res; 1984 Jan; 44(1):259-64. PubMed ID: 6606488 [TBL] [Abstract][Full Text] [Related]
9. Elimination of clonogenic tumor cells from human bone marrow using a combination of monoclonal antibody:ricin A chain conjugates. Bregni M; De Fabritiis P; Raso V; Greenberger J; Lipton J; Nadler L; Rothstein L; Ritz J; Bast RC Cancer Res; 1986 Mar; 46(3):1208-13. PubMed ID: 3510720 [TBL] [Abstract][Full Text] [Related]
10. XomaZyme-CD5 immunotoxin in conjunction with partial T cell depletion for prevention of graft rejection and graft-versus-host disease after bone marrow transplantation from matched unrelated donors. Koehler M; Hurwitz CA; Krance RA; Coustan-Smith E; Williams LL; Santana V; Ribeiro RC; Brenner MK; Heslop HE Bone Marrow Transplant; 1994 May; 13(5):571-5. PubMed ID: 7519937 [TBL] [Abstract][Full Text] [Related]
11. Immunotoxin depletion of T cells and its effect on hematopoietic progenitor cells in human cord blood. Xu M; Lu S; Shen B; Li Y Chin Med J (Engl); 2001 Apr; 114(4):355-9. PubMed ID: 11780453 [TBL] [Abstract][Full Text] [Related]
12. Cytotoxic effect of anti-Mr 67,000 protein immunotoxins on human tumors in a nude mouse model. Weil-Hillman G; Runge W; Jansen FK; Vallera DA Cancer Res; 1985 Mar; 45(3):1328-36. PubMed ID: 3971376 [TBL] [Abstract][Full Text] [Related]
13. Selective killing of human T-lymphotropic virus-I infected leukemic T-cells by monoclonal anti-interleukin 2 receptor antibody-ricin A chain conjugates: potentiation by ammonium chloride and monensin. Krönke M; Schlick E; Waldmann TA; Vitetta ES; Greene WC Cancer Res; 1986 Jul; 46(7):3295-8. PubMed ID: 3011246 [TBL] [Abstract][Full Text] [Related]
14. Thy 1.2+ leukemia cells eradicated from in vitro leukemia-bone marrow cell mixtures by antibody-toxin conjugates. Colombatti M; Colombatti A; Blythman HE; Bron C J Natl Cancer Inst; 1984 May; 72(5):1095-9. PubMed ID: 6585586 [TBL] [Abstract][Full Text] [Related]
15. Antigenic modulation by anti-CD5 immunotoxins. Manske JM; Buchsbaum DJ; Azemove SM; Hanna DE; Vallera DA J Immunol; 1986 Jun; 136(12):4721-8. PubMed ID: 3086441 [TBL] [Abstract][Full Text] [Related]
16. [Selective cytotoxicity of antibody-ricin-A-chain conjugate for human tumor B cells. II. Comparison of activity of immunotoxins conjugated with poly- and monoclonal antibodies]. Tonevitskiĭ AG; Zhukova OS; Rakhmanova VA; Arsen'eva EL; Bogacheva GT Mol Biol (Mosk); 1988; 22(4):911-6. PubMed ID: 3141780 [TBL] [Abstract][Full Text] [Related]
17. Role of immunoregulatory donor T cells in suppression of graft-versus-host disease following donor leukocyte infusion therapy. Johnson BD; Becker EE; LaBelle JL; Truitt RL J Immunol; 1999 Dec; 163(12):6479-87. PubMed ID: 10586039 [TBL] [Abstract][Full Text] [Related]
18. Immunotherapeutic strategies in neuroblastoma: antitumoral activity of deglycosylated Ricin A conjugated anti-GD2 antibodies and anti-CD3xanti-GD2 bispecific antibodies. Manzke O; Russello O; Leenen C; Diehl V; Bohlen H; Berthold F Med Pediatr Oncol; 2001 Jan; 36(1):185-9. PubMed ID: 11464879 [TBL] [Abstract][Full Text] [Related]
19. Amelioration of acute graft-versus-host disease and re-establishment of tolerance by short-term treatment with an anti-TCR antibody. Maeda T; Eto M; Lin T; Nishimura Y; Kong YY; Nomoto K; Nomoto K J Immunol; 1994 Nov; 153(9):4311-20. PubMed ID: 7930630 [TBL] [Abstract][Full Text] [Related]
20. Clinical-scale selective depletion of alloreactive T cells using an anti-CD25 immunotoxin. Michálek J; Collins RH; Vitetta ES Neoplasma; 2003; 50(4):296-9. PubMed ID: 12937844 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]